Showing 131-140 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Network-based Systems Biology for T1D Drug Repositioning | The Regents of the University of California, Los Angeles | Xia Yang | Improving Lives | 01-May-2021 to 30-November-2025 | $780,961.09 |
| Investigation of novel local immunomodulating strategies to enhance islet transplantation for T1D | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-July-2022 to 30-June-2026 | $962,995.99 |
| Prevascularized encapsulation platform with local immunosuppression for Islet transplantation | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-August-2021 to 31-January-2026 | $660,000.00 |
| Tolerance inducing NanoLymph for in vivo generation of islet autoantigen-specific regulatory T cells | The Methodist Hospital Research Institute | Ying Xuan Chua | Cures | 01-April-2025 to 31-March-2026 | $200,000.00 |
| Defining the cell surface glycoproteome and glycome of human islets to enable single cell analysis of human β-cells | The Medical College of Wisconsin Inc. | John Corbett | Cures | 01-October-2022 to 30-September-2025 | $750,000.00 |
| Transcriptional modulation by BET bromodomain inhibitors in beta cells | The Medical College of Wisconsin Inc. | Joshua Nord | Cures | 01-March-2023 to 28-February-2026 | $221,638.00 |
| A prodrug system for targeted activation of small molecules in beta cells | The Brigham and Women’s Hospital, Inc. | Amit Choudhary | Cures | 01-February-2024 to 31-January-2027 | $2,250,000.00 |
| Expanding Access to T1D Care through the PEN-Plus Strategy | The Brigham and Women’s Hospital, Inc. | Gene Bukhman | Mission | 01-August-2024 to 31-July-2027 | $5,999,961.29 |
| Exploiting CRISPR Strategy to Modify T-Cell Lipid Signaling and Mitigate T1D Development | The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham | Sasanka Ramanadham | Cures | 01-May-2023 to 30-April-2025 | $199,989.05 |
| Novel Combination Regimen Therapy to Modulate Pro- and Anti-inflammatory Lipid Signaling to Counter T1D | The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham | Sasanka Ramanadham | Cures | 01-July-2022 to 30-June-2025 | $600,000.00 |